Skip to main content
. 2023 May 9;14(18):1774–1781. doi: 10.1111/1759-7714.14922

TABLE 3.

PD‐L1 and LN pathological characteristics.

Outcomes All patients TPS <1% TPS 1–49% TPS ≥50% p‐value
n = 291 n = 145 n = 108 n = 38
Pathological N stage
pN1/2 40 (13.7) 11 (7.6) 18 (16.7) 11 (28.9) 0.002
pN0 251 (86.3) 134 (92.4) 90 (83.3) 27 (71.1)
Lymph node metastasis
Multiple 16 (5.5) 5 (3.4) 4 (3.7) 7 (18.4) <0.001
Single 24 (8.2) 6 (4.1) 13 (12.0) 5 (13.2)
None 251 (86.3) 134 (92.4) 91 (84.3) 26 (68.4)
N upstaging group outcomes All patients TPS <1% TPS 1–49% TPS ≥50% p‐value
n = 40 n = 11 n = 18 n = 11
Maximum axial diameter (mm)
Mean (± SD) 7.2 ± 3.0 6.3 ± 1.6 6.8 ± 2.4 8.7 ± 4.2 0.346
Tumor invasive diameter (mm)
Mean (± SD) 4.6 ± 2.8 3.6 ± 2.0 4.4 ± 2.0 5.9 ± 4.0 0.309
Tumor‐to‐lymph node ratio
Mean (± SD) 63.4 ± 24.0 57.1 ± 26.1 67.0 ± 25.7 64.2 ± 19.9 0.602

Note: Values for categorical variables were presented as n (%) and assessed with the Fisher's exact test. Variables for continuous variables were expressed as mean and range and were examined using the Kruskal‐Wallis test.

Abbreviations: PD‐L1, programmed death‐ligand‐1; SD, standard deviation; TPS, Tumor Proportion Score.